<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02832102</url>
  </required_header>
  <id_info>
    <org_study_id>H2020-PHC30-689715</org_study_id>
    <nct_id>NCT02832102</nct_id>
  </id_info>
  <brief_title>Big Data and Models for Personalized Head and Neck Cancer Decision Support (BD2Decide)</brief_title>
  <acronym>BD2Decide</acronym>
  <official_title>Big Data and Models for Personalized Head and Neck Cancer Decision Support (BD2Decide)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria di Parma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Superiore di Sanità</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria di Parma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine new multiscale signatures for the prediction of
      head and neck cancer (HNC) patients disease outcome, in particular for advanced stage (stage
      III, IV) human papillomavirus (HPV) negative patients and to validate prognostic models for
      overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical study is devoted to the validation of a decision support system for HNC patients
      management in the frame of a H2020 project.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Realizes and validates an Integrated Decision Support System (BD2Decide platform)</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>The primary endpoint of this study is the accuracy of the prediction of prognosis based on the BD2Decide platform compared to Tumor Node Metastasis staging (in a population consisting of patients with different subtypes of head and neck cancer).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved Quality of Life</measure>
    <time_frame>baseline, month 6, month 18, month 24 after primary treatment</time_frame>
    <description>To measure patients' QoL in relation to the new prognostic stratification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess survival time</measure>
    <time_frame>at 2, 3 and 5 years</time_frame>
    <description>Overall survival and disease free survival will be assessed to verify the accuracy of the prediction of BD2Decide platform</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1450</enrollment>
  <condition>Cancer of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Retrospective cohort</arm_group_label>
    <description>A total of 1000 SCCHN patients will be enrolled in a retrospective observational study treated in the period 2008-2014.
Standard treatment of SCCHN patients The patients will be managed as foreseen by best clinical practice and international guidelines for SCCHN.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective cohort</arm_group_label>
    <description>A total of 450 SCCHN patients will be enrolled in a study. Each participating Center will select consecutive patients according to the selection criteria (inclusion/exclusion criteria) for one year and will be followed up for two years or more.
Standard treatment of SCCHN patients: patients will be administered current best clinical practice treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard treatment of SCCHN patients</intervention_name>
    <description>The interventions may include surgery, radiotherapy, chemotherapy or combined therapies, as recommended by best practice and international guidelines.</description>
    <arm_group_label>Retrospective cohort</arm_group_label>
    <arm_group_label>Prospective cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      FFPE tumor specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Prospective study cohort: A total of 450 SCCHN patients Stage III and IV, followed up for
        18-24 months or more.

        Retrospective study cohort: A total of 1000 SCCHN patients Stage III and IV, diagnosed
        between year 2008 and 2014.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Histologically confirmed diagnosis of oral cavity, oropharynx, larynx, hypopharynx
             squamous cell carcinoma

          -  Clinical stage III and IV

          -  Patient candidate for curative treatment: ± surgery ± radiotherapy ± chemotherapy

          -  Adequate archival pre-treatment tumor specimen available (FFPE macrodissected
             sections)

          -  Availability of baseline diffusion-weighted imaging (DWI) - Magnetic Resonance Imaging
             (MRI) acquisition (non-TRACE ) with more than 3 b-values (ranging from 0 (included) to
             1000 s/mm2), and a field map acquisition.

          -  MRI images, T1 and T2 weighted, (slice thickness lower than 3 mm), head and neck in a
             single volume, and/or CT scan of the head and neck performed with contiguous cuts of
             2-3 mm or less in slice thickness with i.v. contrast

          -  Male or female ≥ 18 years old

        Exclusion Criteria:

          -  Any previous haed and neck cancer.

          -  Patients with previous malignancies in the last 5 years before treatment for head and
             neck cancer, with the exception of surgically cured carcinoma in situ of the cervix,
             in situ breast cancer, incidental finding of stage T1a or T1b prostate cancer, and
             basal/squamous cell carcinoma of the skin.

          -  Any previous malignancy that was treated with surgery and or radiation of the head and
             neck region.

          -  Histological type other than head and neck squamous cell cancer (nasopharynx, salivary
             glands and sinus nasal cancer are excluded).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tito Poli, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria di Parma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tito Poli, MD, PhD</last_name>
    <phone>+39052170</phone>
    <phone_ext>3613</phone_ext>
    <email>tito.poli@unipr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Licitra, MD, PhD</last_name>
    <phone>+39 022390</phone>
    <phone_ext>2150</phone_ext>
    <email>lisa.licitra@istitutotumori.mi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heinrich-Heine Universitaet Dusseldorf, Dept. of Othorinolaryngology, HHU</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathrin Scheckenbach, MD, PhD</last_name>
      <phone>+4981211811</phone>
      <phone_ext>7570</phone_ext>
      <email>Scheckenbach@med.uni-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Lena Colter, MD, PhD</last_name>
      <email>Lena.Colter@med.uni-duesseldorf.de</email>
    </contact_backup>
    <investigator>
      <last_name>Kathrin Scheckenbach, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jörg Schipper, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lena Colter, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Irccs Istituto Dei Tumori Milano</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LISA LICITRA, MD, PhD</last_name>
      <phone>+39 022390</phone>
      <phone_ext>2150</phone_ext>
      <email>lisa.licitra@istitutotumori.mi.it</email>
    </contact>
    <contact_backup>
      <last_name>Federica Favales</last_name>
      <phone>+39 022390</phone>
      <phone_ext>3287</phone_ext>
      <email>federica.favales@istitutotumori.mi.it</email>
    </contact_backup>
    <investigator>
      <last_name>Lisa Licitra, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gemma Gatta, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Federica Favales, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annalisa Trama, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loris De Cecco, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TITO POLI, MD, PhD</last_name>
      <phone>+390521703109</phone>
      <email>tito.poli@unipr.it</email>
    </contact>
    <contact_backup>
      <last_name>Davide Lanfranco, MD, PhD</last_name>
      <phone>+390521703109</phone>
      <email>lanfranco82@yahoo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Enrico M Silini, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tito Poli, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Maglietta, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caterina Caminiti, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stichting VU/VUmc</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maastricht Radiation Oncology MAASTRO Clinic</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe lambin, MD, PhD</last_name>
      <phone>+31 88 445 5585</phone>
      <email>philippe.lambin@maastro.nl</email>
    </contact>
    <contact_backup>
      <last_name>Frank Hoebers, MD, PhD</last_name>
      <phone>+31 88 4455666</phone>
      <email>frank.hoebers@maastro.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Philippe lambin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Hoebers, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adriana Berlanga, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero-Universitaria di Parma</investigator_affiliation>
    <investigator_full_name>Tito Poli</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>prognostic modelling</keyword>
  <keyword>radiomics</keyword>
  <keyword>clinical decision support system</keyword>
  <keyword>big data analysis</keyword>
  <keyword>multiscale prognostic signatures</keyword>
  <keyword>patient-clinician co-decision tools</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patients' data are pseudonymised and stored in a shared Case Report Form (CRF) for data analysis</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

